SOPHiA GENETICS CPO files initial share holdings

SOPHiA GENETICS SA Chief People Officer Manuela Valente filed an initial statement of beneficial ownership.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief People Officer Manuela Valente filed an initial statement of beneficial ownership. She reports direct ownership of 152,759 ordinary shares, including 67,994 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time, subject to continued service.

Valente also reports several share option awards over ordinary shares with exercise prices ranging from 3.2000 to 18.0000 per share and expiration dates between 2029 and 2035. These options cover underlying blocks of 10,000, 20,000, 47,170, 92,937, 160,061 and 119,318 ordinary shares, reflecting her equity-based compensation position rather than new market transactions.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Valente Manuela

Role Chief People Officer

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 459,486 contracts (Direct); Ordinary Shares — 152,759 shares (Direct)

Footnotes (5)

1. F1. Includes 67,994 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 1,690 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 18,917 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 20,381 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 27,006 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
2. F2. The share options are fully vested and exercisable.
3. F3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
4. F4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
5. F5. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Manuela Valente’s Form 3 filing for SOPH show?

The Form 3 shows Chief People Officer Manuela Valente’s existing equity holdings in SOPHiA GENETICS SA. It lists ordinary shares she owns directly, restricted stock units that may settle into shares, and multiple share option awards with specified exercise prices and expiration dates.

How many SOPH ordinary shares does Manuela Valente report owning?

Manuela Valente reports direct ownership of 152,759 ordinary shares of SOPHiA GENETICS SA. This figure includes 67,994 ordinary shares issuable upon settlement of four restricted stock unit grants, each vesting over future dates tied to her continued service with the company.

What equity awards besides shares are disclosed for SOPH’s Chief People Officer?

The filing discloses several share option awards over SOPHiA GENETICS SA ordinary shares. These options have exercise prices between 3.2000 and 18.0000 per share, with expiration dates from 2029 through 2035, and each award covers a stated number of underlying ordinary shares.

Are there any restricted stock units (RSUs) reported in SOPH’s Form 3 filing?

Yes. The filing notes 67,994 ordinary shares issuable upon settlement of four RSU grants. Each RSU represents a right to receive one ordinary share, with vesting schedules running in monthly or quarterly installments through 2028, conditioned on continued service with SOPHiA GENETICS SA.

Does Manuela Valente’s Form 3 for SOPH show stock purchases or sales?

The summarized data show no reported purchases or sales, only holdings. The entries describe existing ordinary share ownership, outstanding restricted stock units, and outstanding share options, consistent with an initial statement of beneficial ownership rather than a record of recent trading activity.

What do the option exercise prices and expirations mean for SOPH shares?

Each option award gives Manuela Valente the right to buy SOPHiA GENETICS SA ordinary shares at a fixed exercise price until its expiration date. Prices range from 3.2000 to 18.0000 per share, with expirations between 2029 and 2035, defining her long-term potential share acquisition terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:45 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Valente Manuela

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	152,759(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	01/01/2029	Ordinary Shares	10,000	$3.2	D
Share Option (Right to Buy)	(2)	11/26/2029	Ordinary Shares	10,000	$4.01	D
Share Option (Right to Buy)	(2)	01/28/2031	Ordinary Shares	20,000	$6.31	D
Share Option (Right to Buy)	(2)	07/22/2031	Ordinary Shares	47,170	$18	D
Share Option (Right to Buy)	(3)	04/03/2033	Ordinary Shares	92,937	$4.72	D
Share Option (Right to Buy)	(4)	04/02/2034	Ordinary Shares	160,061	$4.96	D
Share Option (Right to Buy)	(5)	04/02/2035	Ordinary Shares	119,318	$3.29	D

Explanation of Responses:

1. Includes 67,994 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 1,690 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 18,917 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 20,381 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 27,006 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.

2. The share options are fully vested and exercisable.

3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.

4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.

5. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in-fact for Manuela Valente	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)